Last reviewed · How we verify
NCT03992417: GLOBOSTAD
Observational Study of Patients Receiving Dupixent® for Atopic Dermatitis (AD)
trial testing Dupilumab SAR231893 (REGN668) in Dermatitis Atopic in 955 participants. Participants enrolled and being followed up; not accepting new ones.
31 March 2027
Quick facts
| Lead sponsor | Sanofi |
|---|---|
| Status | Active, enrolled |
| Study type | OBSERVATIONAL |
| Enrollment | 955 |
| Start date | 11 June 2019 |
| Primary completion | 31 March 2027 |
| Estimated completion | 31 March 2027 |
| Sites | 114 locations across Italy, Colombia, Finland, Japan, Taiwan, Netherlands, Russia, Belgium |
Drugs / interventions tested
- Dupilumab SAR231893 (REGN668)
Conditions studied
- Dermatitis Atopic — all drugs for Dermatitis Atopic →
Sponsor
Sanofi — full company profile →
Who can join
12 and older, any sex, with Dermatitis Atopic. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Primary Objective: To characterize the patients who receive Dupixent® (dupilumab) for AD in a real-world setting, with respect to their medical history, socio-demographic and disease characteristics, and prior and concomitant treatments of AD Secondary Objectives: * To characterize real-world use patterns of Dupixent® for AD (eg, used regimens, reason for initiation of new treatments, concomitant therapies, treatment durations and reasons for discontinuation and/or switching) * To assess the long-term effectiveness of Dupixent® in AD patients in a real-world setting * To assess comorbid atopic conditions and effects of treatment in comorbid atopic conditions in patients who receive Dupixent® for AD * To collect safety data on study participants
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Baseline Demographics, Comorbidities, Treatment Patterns and Burden of Atopic Dermatitis in Adults and Adolescents from the GLOBOSTAD Long-Term Observational Study.
Calzavara-Pinton P, Čelakovská J, Lapeere H, Holzer G, et al · · 2023 · cited 4× · PMID 37801232 · DOI 10.1007/s12325-023-02644-5 -
One-Year Insights into the GLOBOSTAD Multinational Prospective Observational Study of Patients Receiving Dupilumab for Atopic Dermatitis.
Calzavara-Pinton P, Chu CY, Lapeere H, Rossi M, et al · · 2025 · cited 2× · PMID 39621227 · DOI 10.1007/s12325-024-03049-8
Verify or expand the search:
- PubMed search for NCT03992417
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Dupilumab SAR231893 (REGN668)
Trials testing the same drug.
- NCT06087627 — A Non-interventional Study to Describe the Dupilumab Long-term Treatment, Safety and Patient Reported Outcomes in Chroni · recruiting
- NCT03620747 — Continuation of TRAVERSE- LTS12551 Evaluating Dupilumab Safety in Patients With Asthma (Long-Term Follow-Up) · Phase 3 · completed
- NCT02912468 — A Controlled Clinical Study of Dupilumab in Patients With Bilateral Nasal Polyps · Phase 3 · completed
- NCT02898454 — Controlled Clinical Study of Dupilumab in Patients With Nasal Polyps · Phase 3 · completed
Other recruiting trials for Dermatitis Atopic
Currently open trials in the same condition.
- NCT06790121 — A Study to Investigate the Efficacy and Safety of Subcutaneous Lunsekimig (SAR443765) Compared With Placebo in Adult Par · Phase 2 · active not recruiting
- NCT06686628 — An Open-label, DDI Study to Investigate the Effects of Amlitelimab on the PK of Selected Cytochrome P450 Substrates · Phase 1 · active not recruiting
- NCT06407934 — A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Tre · Phase 3 · active not recruiting
- NCT06241118 — A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in · Phase 3 · recruiting
- NCT05983068 — A Study of Long-term Effect of Dupilumab on Skin Barrier Function in Pediatric Participants With Atopic Dermatitis · Phase 4 · active not recruiting
Other Sanofi trials
Trials by the same sponsor.
- NCT07282795 — Post-marketing Surveillance Study for the Safety of Efluelda® Pre-filled Syringe · not yet recruiting
- NCT06694025 — Post-marketing Surveillance Study for the Safety of Efluelda Tetra Pre-filled Syringe. · not yet recruiting
- NCT07222189 — A Study to Investigate the Long-term Safety, Tolerability and Efficacy of Balinatunfib in Participants With Crohn's Dise · Phase 2 · not yet recruiting
- NCT07484230 — A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Adult Japanese Partic · Phase 3 · not yet recruiting
- NCT07547436 — A Study to Access Activity and Safety With SAR445399 Compared With Placebo in Participants Aged 18 to 80 Years of Age Wi · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03992417 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Sanofi
- Last refreshed: 11 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03992417.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing